The European healthcare sector is sitting on a transformation that most investors outside the continent have not yet properly valued. AI-powered diagnostics — from radiology triage to pathology pattern recognition — are moving from pilot programmes to clinical deployment at a pace that has accelerated markedly since late 2025.
I have spent the past few months evaluating AI healthcare companies across Europe through NexaTech Ventures, and what I see in our deal flow tells a clear story: the most compelling AI diagnostic tools being built today are European, and they are European for structural reasons that will not change.
The Regulatory Advantage No One Talks About
There is an assumption in Silicon Valley that European regulation is a drag on innovation. In healthcare AI, the opposite is true. The EU Medical Device Regulation and the CE marking process create a compliance framework that, once navigated, provides a defensible market position. A European AI diagnostic tool that has achieved CE Class IIa certification has completed a process that takes between twelve and twenty-four months. That is twelve to twenty-four months of safety and efficacy validation that a competitor cannot shortcut.
American competitors entering the European market must go through the same process from scratch. They cannot port their FDA clearance. The practical effect is a structural moat for European companies that have already built their products within the EU regulatory architecture.
At NexaTech Ventures, this is one of the clearest signals we look for: has the team built compliance into the product architecture from day one, or are they planning to bolt it on later? The former is investable. The latter is a time bomb.
Where the Breakthroughs Are Happening
Three subsectors within AI diagnostics are producing genuinely differentiated technology in Europe right now.
The first is AI-assisted radiology. Several European companies have developed algorithms that can triage chest X-rays, mammograms, and CT scans with sensitivity rates that match or exceed consultant radiologists in specific, well-defined tasks. The important nuance here is the phrase “well-defined tasks.” These systems are not replacing radiologists. They are handling the high-volume screening work that consumes radiologist time, allowing human expertise to be directed at complex cases where clinical judgement is irreplaceable.
The second is digital pathology. The digitisation of tissue slides, combined with deep learning models trained on large European biobank datasets, is enabling pathology analysis at a speed and consistency that manual microscopy cannot match. The UK, Germany, and the Netherlands are leading in this space, partly because their national biobank infrastructure provides the training data that these models require.
The third is clinical decision support — systems that sit at the interface between diagnostic data and treatment pathways. These tools do not make diagnoses. They synthesise patient data, imaging results, lab values, and clinical guidelines to present clinicians with structured decision-support information. The regulatory requirements for these systems are substantial, which is precisely why early movers with robust validation data will be difficult to displace.
The Data Ecosystem That Gives Europe Its Edge
AI diagnostic models are only as good as the data they are trained on, and Europe has a structural advantage in healthcare data that is chronically underappreciated. The UK’s NHS provides a single-payer dataset of sixty-seven million patients. Germany’s statutory health insurance system covers ninety percent of the population. The Nordic countries have population-level health registries that span decades.
These datasets, when accessed through the proper governance frameworks — ethics committees, data protection impact assessments, GDPR-compliant processing agreements — provide training data of a breadth and depth that no private dataset in the United States can match. The challenge has historically been access and interoperability. That is changing, driven partly by the European Health Data Space initiative, which aims to create a cross-border framework for health data sharing by 2025.
The companies that are building their data partnerships now — securing research agreements with hospital trusts, integrating with national radiology networks, establishing validation cohorts across multiple European jurisdictions — are building competitive positions that will be extremely difficult to replicate.
What I Am Backing and Why
At NexaTech Ventures, our healthcare AI portfolio is concentrated in companies that meet three criteria. First, they have a genuine data advantage — either proprietary datasets, exclusive partnerships with health systems, or validated models trained on population-level data. Second, they are building within the regulatory framework rather than around it. Third, their clinical validation strategy is rigorous enough to satisfy both regulators and the procurement committees of major European hospital groups.
We are less interested in companies that are building generic AI wrappers over existing clinical tools. The margin compression in that segment is already evident, and the barrier to entry is too low to produce defensible businesses.
The European AI healthcare diagnostic market is, in my assessment, the single most undervalued opportunity in European technology. The combination of structural regulatory advantage, unmatched public health datasets, and a talent pipeline that spans clinical medicine, computer science, and regulatory affairs creates an environment that Silicon Valley cannot easily replicate.
If you are building in this space, or investing in it, the window to establish position is now. The large US diagnostic companies are already looking at European acquisitions. The companies that build strong clinical evidence and regulatory credentials in the next eighteen months will be the ones they acquire — or the ones that compete with them.
Scott Dylan is the Founder of NexaTech Ventures, a early-stage AI investment fund based in Dublin and California. He writes regularly on AI, venture capital, and technology policy. (Disclaimer: Scott Dylan is not a shareholder of Nexatech Ventures)
